401 related articles for article (PubMed ID: 22356831)
21. RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer.
Olczak P; Matsui K; Wong M; Alvarez J; Lambert P; Christensen ND; Hu J; Huber B; Kirnbauer R; Wang JW; Roden RBS
J Virol; 2022 Jul; 96(13):e0056622. PubMed ID: 35703545
[TBL] [Abstract][Full Text] [Related]
22. Development of a non-denaturing electrophoresis system for characterization of neutralizing epitopes on HPV virus-like particles.
Studentsov YY; Burk RD
J Virol Methods; 2007 Feb; 139(2):208-19. PubMed ID: 17137641
[TBL] [Abstract][Full Text] [Related]
23. Characterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitope.
Olcese VA; Chen Y; Schlegel R; Yuan H
BMC Microbiol; 2004 Jul; 4():29. PubMed ID: 15260888
[TBL] [Abstract][Full Text] [Related]
24. N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro.
Wei M; Wang D; Li Z; Song S; Kong X; Mo X; Yang Y; He M; Li Z; Huang B; Lin Z; Pan H; Zheng Q; Yu H; Gu Y; Zhang J; Li S; Xia N
Emerg Microbes Infect; 2018 Sep; 7(1):160. PubMed ID: 30254257
[TBL] [Abstract][Full Text] [Related]
25. Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.
Culp TD; Spatz CM; Reed CA; Christensen ND
Virology; 2007 May; 361(2):435-46. PubMed ID: 17222883
[TBL] [Abstract][Full Text] [Related]
26. Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31.
Fleury MJ; Touzé A; Alvarez E; Carpentier G; Clavel C; Vautherot JF; Coursaget P
Arch Virol; 2006 Aug; 151(8):1511-23. PubMed ID: 16508703
[TBL] [Abstract][Full Text] [Related]
27. In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.
Namvar A; Bolhassani A; Javadi G; Noormohammadi Z
Sci Rep; 2019 Oct; 9(1):15225. PubMed ID: 31645650
[TBL] [Abstract][Full Text] [Related]
28. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
Wang JW; Jagu S; Wang C; Kitchener HC; Daayana S; Stern PL; Pang S; Day PM; Huh WK; Roden RB
PLoS One; 2014; 9(7):e101576. PubMed ID: 24999962
[TBL] [Abstract][Full Text] [Related]
29. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
30. Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles.
Hanumantha Rao N; Baji Babu P; Rajendra L; Sriraman R; Pang YY; Schiller JT; Srinivasan VA
Vaccine; 2011 Oct; 29(43):7326-34. PubMed ID: 21803095
[TBL] [Abstract][Full Text] [Related]
31. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.
Tumban E; Peabody J; Peabody DS; Chackerian B
PLoS One; 2011; 6(8):e23310. PubMed ID: 21858066
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
[TBL] [Abstract][Full Text] [Related]
33. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies.
Christensen ND; Dillner J; Eklund C; Carter JJ; Wipf GC; Reed CA; Cladel NM; Galloway DA
Virology; 1996 Sep; 223(1):174-84. PubMed ID: 8806551
[TBL] [Abstract][Full Text] [Related]
34. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.
Yang R; Wheeler CM; Chen X; Uematsu S; Takeda K; Akira S; Pastrana DV; Viscidi RP; Roden RB
J Virol; 2005 Jun; 79(11):6741-50. PubMed ID: 15890912
[TBL] [Abstract][Full Text] [Related]
35. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies.
Bishop B; Dasgupta J; Klein M; Garcea RL; Christensen ND; Zhao R; Chen XS
J Biol Chem; 2007 Oct; 282(43):31803-11. PubMed ID: 17804402
[TBL] [Abstract][Full Text] [Related]
36. Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles.
Zhao Q; Allen MJ; Wang Y; Wang B; Wang N; Shi L; Sitrin RD
Nanomedicine; 2012 Oct; 8(7):1182-9. PubMed ID: 22306156
[TBL] [Abstract][Full Text] [Related]
37. Mapping of human serum-reactive epitopes in virus-like particles of human papillomavirus types 16 and 11.
Wang X; Wang Z; Christensen ND; Dillner J
Virology; 2003 Jun; 311(1):213-21. PubMed ID: 12832218
[TBL] [Abstract][Full Text] [Related]
38. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes.
Thönes N; Müller M
Virology; 2007 Dec; 369(2):375-88. PubMed ID: 17822733
[TBL] [Abstract][Full Text] [Related]
39. Papillomavirus-like particle vaccines.
Schiller JT; Lowy DR
J Natl Cancer Inst Monogr; 2001; (28):50-4. PubMed ID: 11158207
[TBL] [Abstract][Full Text] [Related]
40. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
Slupetzky K; Gambhira R; Culp TD; Shafti-Keramat S; Schellenbacher C; Christensen ND; Roden RB; Kirnbauer R
Vaccine; 2007 Mar; 25(11):2001-10. PubMed ID: 17239496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
